Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Shares Traded Last Trade
  +26.60p +1.72% 1,571.20p 12,275,104 16:35:24
Bid Price Offer Price High Price Low Price Open Price
1,570.20p 1,570.60p 1,570.60p 1,543.40p 1,547.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 30,821.00 4,048.00 73.70 21.3 78,001.6

Glaxosmithkline (GSK) Latest News

More Glaxosmithkline News
Glaxosmithkline Takeover Rumours

Glaxosmithkline (GSK) Share Charts

1 Year Glaxosmithkline Chart

1 Year Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

1 Month Glaxosmithkline Chart

Intraday Glaxosmithkline Chart

Intraday Glaxosmithkline Chart

Glaxosmithkline (GSK) Discussions and Chat

Glaxosmithkline (GSK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-05-22 17:29:381,571.20132,9142,088,344.77O
2019-05-22 17:29:091,571.20133,7022,100,725.82O
2019-05-22 17:12:481,561.7517,810278,146.78O
2019-05-22 17:12:481,561.162,13133,268.23O
2019-05-22 17:11:241,561.744,37268,279.23O
View all Glaxosmithkline trades in real-time

Glaxosmithkline (GSK) Top Chat Posts

DateSubject
22/5/2019
09:20
Glaxosmithkline Daily Update: Glaxosmithkline Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker GSK. The last closing price for Glaxosmithkline was 1,544.60p.
Glaxosmithkline Plc has a 4 week average price of 1,495.40p and a 12 week average price of 1,485.20p.
The 1 year high share price is 1,648.80p while the 1 year low share price is currently 1,408.80p.
There are currently 4,964,461,674 shares in issue and the average daily traded volume is 9,649,243 shares. The market capitalisation of Glaxosmithkline Plc is £78,001,621,821.89.
09/2/2019
13:51
anhar: zicopele: ...Can't figure out the benefits of a dividend myself. The price will fall in line with declared dividend on ex div date. It's about paying a reasonably certain and regular income which is what a large number of longer term investors want from their shares for the same reason that people invest in bonds to earn interest or let property etc. The risks to that income vary according to the source but the principle is the same. Trying to make a return from trading capital is, in contrast, hugely more risky and unpredictable. As for the price fall at xd, that is theoretically true though there are many other forces on share prices all the time so it often isn't that obvious as TM says. Longer than a day or so it isn't true at all because a business isn't static, it continues to deliver profits and cash flow all the time. If the share price was permanently affected by div payments, it would sink to zero after repeated divs over time!
19/12/2018
16:33
wbecki: WOW in space of 7 minutes GSK share price worth 75p less!!!! What changed? Or was it a typo? montyhedge 19 Dec '18 - 11:23 - 18655 of 18691 Looked more into it, GSK great deal 1750p here we come. Walsmley on CNBC 30 minutes time, first interview. 80p dividend at least for 2019, then looks like could be increased, yippee. This deal is the transforming deal GSK been looking for. montyhedge 19 Dec '18 - 11:30 - 18656 of 18691 1675p here we come, I reckon, Walsmley CNBC 12pm London time, 7am New York time, first interview. Should create a lot of buying interest.
07/12/2018
09:40
anhar: Alphorn: anhar - good post. I would not agree with 'proven losers' though - a great company in terms of important medicines over time; the list would be long. A term that I have used before is that these shares are 'bond like'. Big Pharma has to run very fast just to stand still just to replace products going off-patent. By "proven losers" I was referring to their terrible long term share price performance which has been known for some time, it's not just a recent thing caused by the general market fall. I have no idea about the qualities of their products, they may well be a great company in that regard as you say but that is not reflected in the long term share price. You may have noticed that people here report on every tiny little drug development as though it's going to be the next big thing that will turn GSK round. It never is. That could change in future and as an income investor I hope it does as that may lead, eventually, to an increased dividend if my strat doesn't take me out of this share before that, but the number of false starts is very large. The reason that GSK has been such a poor capital share is that this "great company" has long made inadequate profits, not helped by their enormous debt. That debt is set to increase with the latest large US acquisition.
06/12/2018
09:30
anhar: In December 2000, two of the UK's largest pharmaceutical companies, Glaxo Wellcome and SmithKline Beecham came together to form global giant GlaxoSmithKline. At that time, GSK's share price was close to £21, valuing the firm at close to £110bn and putting it in the top three of the FTSE 100. Fast forward almost 18 years and GSK's share price is around £14.75, or about a third lower than at the time of the merger. That’s a bitter pill to swallow for investors as the deal has failed to prevent the destroyal of roughly £30bn of shareholder wealth. TM: Most will be aware of this appalling long term capital performance by GSK. The mystery is why you think it's the one share in which to invest so much, with that history. This is not a new thing, it's been clear for many years that GSK is an awful share for capital gain purposes. I invest only for income and have held for a long time now during which it has done what I wanted on dividends, up to a point though even that's been frozen for years now, but if I was a capital player and willing to risk it all or most on just one stock, I would never consider GSK. They are proven losers, at least over the last 18 years. Long term my dividend stocks have in total done very well on capital, though that's not why I invest this way, but GSK is one of the exceptions. In fact with the market fall pushing up the FTSE100 yield, and GSK's frozen 80p dividend making a yield of 5.6% at 1435p, it's getting closer to my exit point.
05/12/2018
15:49
tradermichael: In December 2000, two of the UK's largest pharmaceutical companies, Glaxo Wellcome and SmithKline Beecham came together to form global giant GlaxoSmithKline. At that time, GSK's share price was close to £21, valuing the firm at close to £110bn and putting it in the top three of the FTSE 100. Fast forward almost 18 years and GSK's share price is around £14.75, or about a third lower than at the time of the merger. That’s a bitter pill to swallow for investors as the deal has failed to prevent the destroyal of roughly £30bn of shareholder wealth. According to collated research and a recent Harvard Business Review report, the failure rate for mergers and acquisitions (M&A) sits between 70 percent and 90 percent.15 Mar 2017
23/11/2018
16:40
barbel3: hi guys so if the dollar drops to the pound does that mean its better for gsk share price just out of interest cheers
02/11/2018
14:05
jadeticl3: What was it that caused the GSK share price to leap 50p on the day of the results announcement, but then fall by 90p. And then by more thereafter?
02/10/2018
08:37
mr woodentop: Blimey - sounds like the daily express yesterday with 'pound goes ballistic'. It was up 0.3%. Today it is down by about the same amount. The GSK share price, although affected by the £ should not be totally dependent on it. The BOD's actions should be making it rise over the mid to long term. Jury is still out on that one though! keep taking the divis
04/11/2017
08:11
tradermichael: 20 years ago, in September 1997, the GSK share price rose from today's price to 2068p one year later ........
01/7/2017
08:26
tradermichael: m_k_hubbert - yes, and for my trades at £150K, I factor in a 7.5p increase in GSK share price is required for my costs to break even. ..... ;0)
Glaxosmithkline share price data is direct from the London Stock Exchange
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190523 03:04:17